Athersys, Inc. (ATHXQ)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Jan 27, 2025, 9:30 AM EST
-100.00%
Market Cap 62.00
Revenue (ttm) 80.00K
Net Income (ttm) -37.51M
Shares Out 61.75M
EPS (ttm) -1.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 231
Average Volume 2,482
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta 4.26
RSI 44.84
Earnings Date n/a

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrom... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 24
Stock Exchange OTCMKTS
Ticker Symbol ATHXQ
Full Company Profile

Financial Performance

In 2022, Athersys's revenue was $5.33 million, a decrease of -3.43% compared to the previous year's $5.51 million. Losses were -$72.53 million, -16.58% less than in 2021.

Financial Statements

News

There is no news available yet.